QQQ1.35%

Trending

XRP4.05%

Info

home Symbol AMLXnews

Exchange: NASDAQ·Updated 05:12 AM EDT

AMLXAmylyx Pharmaceuticals Inc

$17.60

$0.15

(0.86%)

Pre-Market

Prev Close $17.45

EarningsAug 6

Mkt Cap$1.97B

Vol35.00

News

all

press releases

Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders? Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders? PR Newswire NEW YORK, July 3, 2026 Shareholders are encouraged to contact the firm to discuss their rights and options at...

PR Newswire

More News

Is Amylyx Pharmaceuticals, Inc. (AMLX) Stock Ready for a Breakout Ahead of Key LUCIDITY Trial Data?

Is Amylyx Pharmaceuticals, Inc. (AMLX) Stock Ready for a Breakout Ahead of Key LUCIDITY Trial Data...

Yahoo! Finance: News

Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (Amylyx or the Company) today announced the presentation of data from its first-in-human, dose-ranging Phase 1 LUMINA trial of AMX0114 at the European Network to Cure ALS (ENCALS) Meeting 2026, held from June 24-26, 2026 in Madrid, Spain. AMX0114 showed...

Business Wire

Amylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (Amylyx or the Company) today announced two poster presentations at the upcoming Endocrine Societys Annual Meeting (ENDO 2026), taking place June 13-16, 2026, in Chicago, IL. The first presentation characterizes the overall burden of post-bariatric...

Business Wire

Amylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label HELIOS Trial Data for AMX0035 in The Journal of Clinical Investigation

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (Amylyx or the Company) today announced that Week 24 and Week 48 results from the Phase 2 open-label HELIOS clinical trial of AMX0035, an oral, fixed-dose...

Business Wire

Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (Amylyx or the Company) today reported financial and business results for the first quarter ended March 31, 2026. With enrollment complete in the pivotal...

Business Wire

Amylyx Pharmaceuticals Announces U.S. Expanded Access Program for Adults with Post-Bariatric Hypoglycemia

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (Amylyx or the Company) today announced the launch of a U.S. Expanded Access Program (EAP) for up to 250 adults with post-bariatric hypoglycemia (PBH) to provide treatment access to avexitide, an investigational, first-in-class glucagon-like peptide-1...

Business Wire

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Given Consensus Recommendation of "Moderate Buy" by Analysts

Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) have been given a consensus rating of "Moderate Buy" by the fourteen analysts that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, two have assigned a hol...

MarketBeat

Amylyx Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (Amylyx or the Company) will report its first quarter 2026 financial results on Thursday, May 7, 2026. Amylyxs senior management team will host a conference call and audio webcast at 8:00 a.m. ET to discuss the financial results and other company updates...

Business Wire

Amylyx Pharmaceuticals (AMLX) Projected to Post Quarterly Earnings on Thursday

Amylyx Pharmaceuticals (NASDAQ:AMLX) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at...

MarketBeat

...

Advertisement|Remove ads.